These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

717 related articles for article (PubMed ID: 27367583)

  • 1. Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis.
    Spring LM; Gupta A; Reynolds KL; Gadd MA; Ellisen LW; Isakoff SJ; Moy B; Bardia A
    JAMA Oncol; 2016 Nov; 2(11):1477-1486. PubMed ID: 27367583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant endocrine therapy in locally advanced estrogen or progesterone receptor-positive breast cancer: determining the optimal endocrine agent and treatment duration in postmenopausal women-a literature review and proposed guidelines.
    Madigan LI; Dinh P; Graham JD
    Breast Cancer Res; 2020 Jul; 22(1):77. PubMed ID: 32690069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The tumour response of postmenopausal hormone receptor-positive breast cancers undergoing different types of neoadjuvant therapy: a meta-analysis.
    Wang Y; He L; Song Y; Wu Q; Wang H; Zhang B; Ma X
    BMC Womens Health; 2020 Jan; 20(1):17. PubMed ID: 32005117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in ER-positive Breast Cancer: Results From a Prospective Institutional Database.
    LeVasseur N; Willemsma KA; Li H; Gondara L; Yip WC; Illmann C; Chia SK; Simmons C
    Clin Breast Cancer; 2019 Dec; 19(6):e683-e689. PubMed ID: 31279611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant endocrine treatment in hormone receptor-positive breast cancer: Does it result in more breast-conserving surgery?
    van de Loo ME; Andour L; van Heesewijk AE; Oosterkamp HM; Liefers GJ; Straver ME
    Breast Cancer Res Treat; 2024 May; 205(1):5-16. PubMed ID: 38265568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?
    Freedman OC; Verma S; Clemons MJ
    Cancer Treat Rev; 2005 Feb; 31(1):1-17. PubMed ID: 15707700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclin-dependent kinase 4 and 6 inhibitors in combination with neoadjuvant endocrine therapy in estrogen receptor-positive early breast cancer: a systematic review and meta-analysis.
    Guan Y; Shen G; Fang Q; Xin Y; Huo X; Li J; Zhao F; Ren D; Liu Z; Li Z; Zhao J
    Clin Exp Med; 2023 Jun; 23(2):245-254. PubMed ID: 35304677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
    Semiglazov VF; Semiglazov VV; Dashyan GA; Ziltsova EK; Ivanov VG; Bozhok AA; Melnikova OA; Paltuev RM; Kletzel A; Berstein LM
    Cancer; 2007 Jul; 110(2):244-54. PubMed ID: 17538978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiological, pathological and surgical outcomes after neoadjuvant endocrine treatment in patients with ER-positive/HER2-negative breast cancer with a clinical high risk and a low-risk 70-gene signature.
    van Olmen JP; Jacobs CF; Bartels SAL; Loo CE; Sanders J; Vrancken Peeters MTFD; Drukker CA; van Duijnhoven FH; Kok M
    Breast; 2024 Jun; 75():103726. PubMed ID: 38599047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
    Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
    Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term outcomes of neoadjuvant hormonal therapy versus neoadjuvant chemotherapy in breast cancer: systematic review and meta-analysis of randomized controlled trials.
    Huang L; Xu AM
    Expert Rev Anticancer Ther; 2017 Apr; 17(4):327-334. PubMed ID: 28271747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Landmark Series: Neoadjuvant Endocrine Therapy for Breast Cancer.
    Weiss A; King TA; Mittendorf EA
    Ann Surg Oncol; 2020 Sep; 27(9):3393-3401. PubMed ID: 32591951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer.
    Kim HJ; Noh WC; Lee ES; Jung YS; Kim LS; Han W; Nam SJ; Gong G-; Kim HJ; Ahn SH
    Breast Cancer Res; 2020 May; 22(1):54. PubMed ID: 32460816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and acceptability of neoadjuvant endocrine therapy in patients with hormone receptor-positive breast cancer: A network meta-analysis.
    Zhang T; Feng F; Yao Y; Qi L; Tian J; Zhou C; Dong S; Wang X; Sun C
    J Cell Physiol; 2019 Aug; 234(8):12393-12403. PubMed ID: 30652307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus).
    Hind D; Wyld L; Beverley CB; Reed MW
    Cochrane Database Syst Rev; 2006 Jan; (1):CD004272. PubMed ID: 16437480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lessons in precision oncology from neoadjuvant endocrine therapy trials in ER+ breast cancer.
    Ellis MJ
    Breast; 2017 Aug; 34 Suppl 1(Suppl 1):S104-S107. PubMed ID: 28669712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients--a phase II trial.
    Fontein DB; Charehbili A; Nortier JW; Meershoek-Klein Kranenbarg E; Kroep JR; Putter H; van Riet Y; Nieuwenhuijzen GA; de Valk B; Terwogt JM; Algie GD; Liefers GJ; Linn S; van de Velde CJ
    Eur J Cancer; 2014 Sep; 50(13):2190-200. PubMed ID: 24970786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Utility of Neoadjuvant Endocrine Therapy for Hormone Receptor Positive Breast Cancer.
    Kolberg HC; Aktas B; Liedtke C
    Rev Recent Clin Trials; 2017; 12(2):67-72. PubMed ID: 28155606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant endocrine therapy for resectable breast cancer: A systematic review and meta-analysis.
    Leal F; Liutti VT; Antunes dos Santos VC; Novis de Figueiredo MA; Macedo LT; Rinck Junior JA; Sasse AD
    Breast; 2015 Aug; 24(4):406-12. PubMed ID: 25858103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.